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Poly(ADP-ribose) polymerase-1 (PARP-1) synthesizes and transfers ADP ribose polymers to target proteins, and regulates DNA
repair and genomic integrity maintenance. PARP-1 also plays a crucial role in the progression of the inflammatory response,
and its inhibition confers protection in several models of inflammatory disorders. Here, we investigate the impact of a selective
PARP-1 inhibitor in experimental arthritis. PARP-1 inhibition with 5-aminoisoquinolinone (AIQ) significantly reduces incidence
and severity of established collagen-induced arthritis, completely abrogating joint swelling and destruction of cartilage and
bone. The therapeutic effect of AIQ is associated with a striking reduction of the two deleterious components of the disease,
i.e. the Th1-driven autoimmune and inflammatory responses. AIQ downregulates the production of various inflammatory
cytokines and chemokines, decreases the antigen-specific Th1-cell expansion, and induces the production of the anti-
inflammatory cytokine IL-10. Our results provide evidence of the contribution of PARP-1 to the progression of arthritis and
identify this protein as a potential therapeutic target for the treatment of rheumatoid arthritis.
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Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response. PLoS ONE 2(10): e1071. doi:10.1371/
journal.pone.0001071
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease that leads to
chronic inflammation in the joints and subsequent destruction of the
cartilage and erosion of the bone. Although its etiology is unknown,
evidences indicate that the recruitment and activation ofneutrophils,
macrophages and lymphocytes into joint tissuesand the formation of
the pannus are hallmarks of the pathogenesis of RA. Although the
contribution of Th1 responses in RA is not completely understood,
several studies in animal models point to a pathogenic role for Th1-
derived cytokines [1–3]. Th1 cells reactive to components of the
joint, infiltrate the synovium, release proinflammatory cytokines and
chemokines, and promote macrophage and neutrophil infiltration
and activation. Inflammatory mediators, such as cytokines and free
radicals, produced by infiltrating inflammatory cells, play a critical
role in joint damage [3,4]. The fact that the inflammatory process in
RA is chronic suggests that immune regulation in the joint is
disturbed. This disturbance is probably caused by an excessive
inflammatory response together with a deficiency in the mechanisms
that control the immune response. Available therapies based on
immunosuppressive agents inhibit the inflammatory component of
RA and have the potential to slow progressive clinical disability by
delaying erosions and deformity (5,6). However, they neither reduce
the relapse rate nor delay disease onset, and because a continued
treatment is required to maintain a beneficial effect, they have
multiple side effects [5,6]. This illustrates the need for novel
therapeutic approaches to prevent the inflammatory and autoim-
mune components of the disease and to promote immune tolerance
restoration.
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear DNA-
binding protein activated by DNA damage, belonging to a family
of more than seventeen members, that catalyzes the attachment of
ADP-ribose to target proteins, acts as a component of enhancer/
promoter regulatory complexes and participates in the regulation
of DNA repair and genomic integrity maintenance [7]. Numerous
studies have also involved PARP-1 in the regulation of the
inflammatory response [8]. Thus, animals treated with PARP-1
inhibitors or PARP-1 deficient mice showed decreased tissue
damage and inflammatory mediators in several models of
ischemia-reperfusion and heart transplantation (reviewed in [9]).
Moreover, mice lacking PARP-1 are extremely resistant to
endotoxin-induced septic shock [10]. The involvement of PARP-
1 in the pathogenesis of autoimmune disorders has been previously
suggested. Thus, PARP-1 inhibition prevented progression of type
1 diabetes, inflammatory bowel disease and experimental
autoimmune encephalomyelitis [11–14]. Interestingly, a promoter
haplotype for PARP-1 has been shown to confer higher
susceptibility for systemic lupus erythematous and RA [15,16].
Therefore, the aim of this study is to investigate the potential
impact of selective PARP-1 inhibition in an experimental model of
RA. Here we show that delayed treatment with a novel PARP-1
inhibitor has great benefit at the clinical and pathological levels, as
its therapeutic action was exerted at multiple levels, being
associated with the downregulation of inflammatory and Th1-
mediated autoimmune components of the disease. These results
provide support for the contribution of PARP-1 in the pathogen-
esis of arthritis and open the possibility that specific PARP-1
inhibitors might become attractive therapeutic tools in RA.
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PARP-1 inhibition decreases severity of
experimental arthritis
Collagen-induced arthritis (CIA) is a murine experimental disease
model that shares a number of clinical, histologic and immuno-
logic features with RA, and it is used as a model system to test
potential therapeutic agents. 5-aminoisoquinolinone (AIQ) is a new
and selective inhibitor of PARP-1 previously used for the
treatment of various ischemic/reperfusion injuries [17,18]. A
single administration of AIQ (1.5 mg/kg) at the onset of the
disease or to mice with established clinical signs of arthritis
progressively attenuated the severity of CIA and decreased the
percentage of mice with arthritis, as compared to untreated mice
(Fig. 1A). We did not observe significant differences in the
therapeutic effect of AIQ at 1.5 mg/kg and 3 mg/kg doses (not
shown). Histopathological analyses of joints showed that AIQ
treatment significantly abrogated CIA-characteristic chronic in-
flammation of synovial tissue (infiltration of inflammatory cells into
the joint cavity and periarticular soft tissue, consisting in
lymphocytes, plasma cells, macrophages and neutrophils), pannus
formation, cartilage destruction and bone erosion (Fig. 1B). The
AIQ-mediated inhibition of neutrophil infiltration was confirmed
with decreased joint myeloperoxidase (MPO) activity (Fig. 1B).
AIQ inhibits inflammatory response in CIA
We next investigated the mechanisms underlying the decrease in
severity of CIA following PARP-1 inhibition. Several evidences
have involved a wide array of cytokines and chemokines in joint
inflammation and the arthritis progression [1,3,19]. We evaluated
the effect of AIQ treatment on the production of inflammatory
mediators that are mechanistically linked to CIA severity. AIQ
administration significantly reduced protein and gene expression
of inflammatory cytokines (TNFa, IFNc, IL-6, IL-1b and IL-12),
chemokines (Rantes and MIP-2) in the joint of arthritic mice
(Fig. 2A). In addition, joints of AIQ-treated mice showed increased
levels of the anti-inflammatory cytokine IL-10 (Fig. 2A). The
broad anti-inflammatory activity of AIQ in the inflamed joint was
accompanied by downregulation of the systemic inflammatory
response. In vivo inhibition of PARP-1 decreased CIA-induced
serum levels of the proinflammatory cytokines TNFa and IL-1b
(Fig. 2B).
In vivo inhibition of PARP-1 downregulates Th1-
mediated CII-specific response in CIA
Although macrophages and neutrophils are the major sources of
inflammatory mediators, CD4 T cells play a key role in the
initiation and perpetuation of CIA by producing IFNc, a potent
inducer of the inflammatory response. In fact, CIA is considered
an archetypal of Th1-type cell-mediated autoimmune disease [1].
Therefore, PARP-1 inhibition could ameliorate CIA by reducing
autoreactive T-cell responses and/or migration to the joints. We
determined proliferation and cytokine profile of draining lymph
node (DLN) cells isolated from AIQ-treated arthritic mice in
response to antigen (CII) in vitro. DLN cells obtained from CIA
mice showed marked CII-specific proliferation and effector T cells
producing high levels of Th1-type cytokines (IFN-c, IL-2 and
TNF-a) and low levels of Th2-type cytokines (IL-4 and IL-10)
(Fig. 3A). In contrast, DLN cells from AIQ-treated mice
proliferated much less, produced low levels of Th1 cytokines
(Fig. 3A). The Th2-type cytokines IL-4 and IL-10 were not
significantly affected (Fig. 3A). This effect was antigen-specific,
because AIQ treatment did not affect proliferation and cytokine
production by anti-CD3-stimulated spleen cells (Fig. 3A). This
suggests that inhibition of PARP-1 during CIA progression
partially inhibits CII-specific Th1-cell clonal expansion. In order
to distinguish whether the decrease in Th1 cytokine production
induced by AIQ treatment is consequence of either down-
regulation of cytokine release or inhibition of Th1 cell expansion,
we determined the intracellular expression of these cytokines by
flow cytometry in sorted CD4 T cells. AIQ significantly decreased
the number of IFNc-producing Th1 cells, although did not affect
the number of IL-4/IL-10-producing CD4 T cells in DLN
(Fig. 3B). We observed similar effects on synovial cells (Fig. 3C).
Thus, in vivo inhibition of PARP-1 on CIA mice regulates the
expansion of autoreactive/inflammatory Th1 cells.
High levels of circulating antibodies directed against collagen
rich joint tissue invariably accompany the development of RA and
CIA, and their production is a major factor in determining
susceptibility to the disease [20]. AIQ administration resulted in
reduced serum levels of CII-specific IgG, particularly autoreactive
IgG2a antibodies (Fig. 3D), generally reflective of Th1 activity.
These data provide further evidence that PARP-1 inhibition
during CIA reduces the Th1 autoreactive responses both in the
joint and periphery.
DISCUSSION
The initial stages of RA and CIA involve multiple steps, which can
be divided into two main phases: initiation and establishment of
autoimmunity, and later events associated with the evolving
immune and inflammatory responses. The crucial process un-
derlying disease initiation is the induction of autoimmunity to
collagen rich joint components; later events involve a destructive
inflammatory process [1,3]. Progression of the autoimmune
response involves the development of autoreactive Th1 cells, their
entry into the joint tissues, and future recruitment of inflammatory
cells through multiple mediators. Certain therapeutic approaches
address the autoimmune component of CIA and RA, comple-
menting existing anti-inflammatory therapies. In this study we
show that a specific and potent inhibitor for PARP-1 provides
a highly effective therapy for CIA. The therapeutic effect of AIQ is
associated with a striking reduction of the two deleterious
components of the disease, i.e. the autoimmune and inflammatory
response. In vivo inhibition of PARP-1 decreased the presence of
autoreactive Th1 cells in the periphery and the joint. In addition,
AIQ strongly reduced the inflammatory response during CIA
progression by downregulating the production of several in-
flammatory mediators, such as various cytokines and chemokines
in the joints. As a consequence, treatment with AIQ reduced the
frequency of arthritis, ameliorated symptoms and avoided joint
damage. From a therapeutic point of view, it is important to take
in account the ability of delayed administration of AIQ to
ameliorate ongoing disease, which fulfills an essential prerequisite
for an anti-arthritic agent, as treatment is started after the onset of
patient arthritis. The fact that we did not observe a loss in its
beneficial effect with time suggests that an initial treatment with
AIQ could induce remission of the disease. Therefore, a long-term
treatment may not be required with AIQ, avoiding the appearance
of potential side effects. AIQ offers therapeutic advantages over
other PARP inhibitors, such as benzamide and the phenanthri-
dinone derivate PJ34, used in several autoimmune models [11–
14]. Thus, PJ34 showed a protective effect on experimental
autoimmune encephalomyelitis, CIA and experimental type 1
diabetes only when administered on a prophylactic regime before
the disease onset, loosing its therapeutic effect in animals with
established clinical signs [13]. In addition, contrary to AIQ, the
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PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1071Figure 1. AIQ decreases CIA severity. DBA1 mice with established CIA were injected i.p. either with PBS (control) or with AIQ (1.5 mg/kg) on day 22
or on day 25. A. Severity of arthritis was assessed by clinical scoring. Numbers in parenthesis represent frequency of arthritis (% mice with arthritis
score.2 at day 35). B. Histological analysis of trichromic-stained (lower) or H&E-stained (upper) sections of joints obtained at day 45 was performed.
Scoring of inflammation, cartilage damage and bone erosion of paws from untreated (control) and AIQ-treated CIA mice is shown. Neutrophil
infiltration in the joints was determined by measuring MPO activity in protein extracts isolated at day 35. n=6–8 mice per group. *p,0.001 versus
control.
doi:10.1371/journal.pone.0001071.g001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1071Figure 2. AIQ administration inhibits inflammatory response in CIA. DBA1 mice with established CIA were injected i.p. either with PBS (control) or
with AIQ (1.5 mg/kg) on day 25 post-immunization. Systemic and local expression of inflammatory mediators was assayed in protein extracts from
joints (A) and sera (B) isolated at day 35 post-immunization. A paw from an unimmunized mouse was analyzed simultaneously for assessment of the
basal response. n=3–4 mice/group. *p,0.001 versus controls.
doi:10.1371/journal.pone.0001071.g002
Figure 3. Inhibition of PARP-1 downregulates Th1-mediated response in CIA. DBA1 mice with established CIA were injected i.p. either with PBS
(control) or with AIQ (1.5 mg/kg) on day 25 post-immunization. A. Proliferative response and cytokine production of DLN cells isolated at day 30 from
untreated (control) or AIQ-treated CIA mice were determined after in vitro stimulation with different concentrations of CII. Stimulation of DLN cells
with anti-CD3 antibodies (., for untreated CIA mice; ,, for AIQ-treated CIA mice) was used for assessment of nonspecific stimulation. A pool of 3
nonimmunized DBA/1 DLN cells was used for assessment of the basal response. No proliferation or cytokine production by T cells was detectable in
the presence of an unrelated antigen (OVA). n=5 mice/group. B, Number of CII-specific cytokine-producing T cells. DLN cells from untreated (control)
or AIQ-treated CIA mice were restimulated in vitro with CII (10 mg/ml) and analyzed for CD4 and intracellular cytokine expression in gated CD4 T cells
by flow cytometry. Dot plots show representative double staining for IFNc/TNFa or IL-4/IL-10 expression in gated CD4 T cells. The number of IFNc-, IL-
4- and IL-10-expressing T cells relative to 10
4 CD4 T cells is shown in the lower panel. Data shown represent pooled values from two independent
experiments. C, CII-specific proliferative response and the number of cytokine-producing CD4 T cells were determined in synovial membrane cells
isolated from untreated (control) or AIQ-treated CIA mice and stimulated in vitro with CII (10 mg/ml) for 48 h. Data show the results of pooled
synovial cells from 3 animals per group. D. AIQ decreases titter of autoantigens in CIA mice. The levels of CII-specific IgG, IgG1 and IgG2a antibodies in
sera collected at day 35 were determined by ELISA. n=3-5 mice/group. *p,0.001 versus controls.
doi:10.1371/journal.pone.0001071.g003
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treatment is terminated [11–14].
The capacity of AIQ to regulate a wide spectrum of
inflammatory mediators might offer a therapeutic advantage over
other treatments directed against a single mediator, such as the
new biologic agents. Chemokines are responsible for the in-
filtration into the joint and activation of various leukocyte
populations, which contribute to CIA pathology (1-3,[21]. The
fact that in vivo inhibition of PARP-1 reduced the expression of
a plethora of chemokines could partially explain the absence of
inflammatory infiltrates in the joint tissues of AIQ-treated mice,
being especially relevant for chemokines as MIP-2 (chemotactic for
neutrophils) and Rantes (for macrophages and T cells), all involved
in CIA pathogenesis [21,22]. Moreover, PARP-1 inhibition
reduced the expression of several proinflammatory chemokines
receptors involved in arthritis pathology (not shown), reflecting
also a decreased joint inflammatory infiltration.
In addition to the regulation of cell recruitment to the joint,
AIQ also regulates the activation of inflammatory cells in the
joints. Thus, AIQ downregulated the production of the proin-
flammatory/cytotoxic cytokines TNFa, IFNc, IL-6, IL-1b and IL-
12 in the inflamed joint, and increased the levels of the anti-
inflammatory cytokine IL-10, which ameliorates the disease [23].
The decrease in inflammatory mediators could be the conse-
quence of a diminished infiltration of inflammatory cells in the
synovium. However, the fact that AIQ inhibited the production of
pro-inflammatory mediators by synovial cells isolated from CIA
mice, argues against this hypothesis (not shown). This suggests
that, in addition to the reduction in inflammatory infiltration, the
inhibition of PARP-1 deactivates the inflammatory response.
Two mechanisms have been proposed to explain the role of
PARP-1 in inflammatory diseases. One potential mechanism is
related to massive PARP-1 activation induced by genotoxic injury
developed during the inflammatory process [24]. In this case,
hyperactivated PARP-1 would lead to rapid ATP depletion and to
irreversible cellular energy failure and necrotic-type cell death
subsequent to disruption of oxidative metabolism. However,
several lines of evidence suggest that under inflammatory
conditions the beneficial effects of PARP-1 inhibition are
independent on the prevention of energy failure (12). The ‘‘suicide
hypothesis’’, therefore, might be valid only in conditions of massive
DNA rupture and intense PARP-1 activation. The other proposed
and more plausible mechanism is related to a functional link
between PARP-1 and inflammation-related transcription factors.
Several in vivo and in vitro studies have demonstrated the
involvement of PARP-1 in the activation of nuclear factor NF-
kB [10,25], a transcription factor that plays a central role in the
regulation of genes involved in the immune and inflammatory
response of RA. Recently, it has also been reported that PARP-1
regulates other transcription factors implicated in stress/inflam-
mation, such as AP-1, Oct-1, SP-1, YY-1 and Stat-1 [26,27].
CIA is also a Th1-mediated disease, and the bias towards Th1
cytokines (mainly IFNc and TNFa) is crucial in the establishment
of chronic inflammation in the joint (1-3). Our results demonstrate
that the administration of AIQ to arthritic mice results in
a decreased CII-specific Th1-mediated response. It appears that
the inhibition of the Th1 response is caused by a direct action on
synovial and DLN cells, since synovial and DLN cells obtained
from AIQ-treated animals are refractory to Th1 cell stimulation.
Whereas the effects of PARP-1 inhibition on the inflammatory
response have been previously suggested by others, the present
study is the first evidence describing the involvement of PARP-1 in
the Th1-mediated autoreactive response. Although the mech-
anisms involved in the inhibitory action of AIQ in Th1 activation
are unknown, our results suggest that AIQ treatment impairs the
proliferation and/or differentiation of antigen-specific Th1 cells.
In this sense, NF-kB and AP-1 are involved in the regulation of the
proliferative response of T cells, and AIQ inhibition of PARP-1-
mediated activation of these transcription factors could play
a major role in this effect. Indeed, other PARP-1 inhibitors have
been found to decrease NF-kB and AP-1 transduction activity in
activated T cells [11].
In summary, this work identifies PARP-1 as a novel therapeutic
target for the treatment of RA and other chronic autoimmune
disorders and provides a powerful rationale for the assessment of
the efficacy of the PARP-1 inhibitor AIQ as a new immunomod-
ulatory factor with the capacity to deactivate the inflammatory
response in vivo at multiple levels.
METHODS
Arthritis induction and treatment
Animal experimental protocols were reviewed and approved by the
Ethical Committee of the Spanish Council of Scientific Research
(CSIC). To induce collagen-induced arthritis (CIA), DBA/1J mice
(7–10-wk-old, Jackson Labs) were injected s.c. with 200 mg of type
II collagen (CII, Sigma) emulsified in complete Freunds adjuvant
(CFA) containing 200 mgo fM. tuberculosis H37 RA (Difco, Detroit,
Michigan). At day 20 after primary immunization, mice were
boosted s.c. with 100 mg of CII in CFA. Treatment with PARP-1
inhibitor (AIQ, Alexis) consisted in a single administration i.p. of
1.5 mg/kg of AIQ (in saline) starting at the disease onset (at day 22
post-immunization) or at 25 days post-immunization when all mice
showed established arthritis (clinical score.2). The dose of AIQ
was selected from previous in vivo studies demonstrating the
efficacy and potency of the drug to inhibit PARP-1 activity without
any resultant toxicity [17,18]. In each experiment, a control group
of mice was injected i.p. with PBS (untreated). Mice were analyzed
by two independent, blinded examiners every other day and scored
for signs of arthritis by using the following system: grade 0, no
swelling; grade 1, slight swelling and erythema; grade 2, moderate
swelling and edema; grade 3, extreme swelling and pronounced
edema; grade 4, joint rigidity. Each limb was graded, giving
a maximum possible score of 16 per animal.
Histopathology analysis
For histological analysis, the paws were randomly collected by two
independent experimenters at day 45 after primary immunization,
fixed in 4% buffered-formaldehyde, decalcified, paraffin-embed-
ded, sectioned and stained with H&E or Masson-Goldner
trichromic stain. Histopathological changes were scored in
a blinded manner based in cell infiltration, cartilage destruction
and bone erosion parameters as described [28]. Neutrophil
infiltration in the joints was monitored by measuring myeloper-
oxidase (MPO) activity in joint extracts isolated at day 35 post-
immunization as described [28].
Cytokine and autoantibody determination
For cytokine determination in joints, protein extracts were isolated
by homogenization of joints (50 mg tissue/ml) in 50 mM Tris-HCl,
pH 7.4, with 0.5 mM DTT, and proteinase inhibitor cocktail
(10 mg/ml, Sigma). Serum samples were collected at peak of disease
(day 35) and the levels of anti-CII IgG, IgG1 and IgG2a Abs were
measured by ELISA as described [29]. Cytokine and chemokine
levels in the serum and joint protein extracts prepared at the disease
peak (day 35) were determined by specific sandwich ELISAs using
capture/biotinylated detection Abs from BD Pharmingen (San
Diego, CA) according to the manufacture’s recommendations.
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Because T cell autoreactive response precedes to maximal clinical
manifestations of the disease, single-cell suspensions (10
6 cells/ml)
from draining lymph nodes (DLN) and synovial membrane of knee
joints were obtained at 30 days post-immunization. Cells were
stimulated in complete medium (RPMI 1640 containing 10%
FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin) with different concentrations of heat-inactivated CII
for 48 h (for cytokine determination) or for 72 h (for proliferative
response) [29]. Cell proliferation was evaluated by using a cell
proliferation assay (BrdU) from Roche Diagnostics GmbH
(Mannheim, Germany). Cytokine content in culture supernatants
was determined by specific sandwich ELISAs as above. For
intracellular analysis of cytokines, DLN and synovial cells were
stimulated with inactivated CII (10 mg/ml) for 8 h, in the presence
of monensin, and then stained with PerCP-anti-CD4 mAbs at
4uC, washed, fixed/saponin permeabilized, stained with FITC-
and PE-conjugated anti-cytokine specific mAbs (BD Pharmingen),
and analyzed on a FACScalibur flow cytometer (Becton
Dickinson). To distinguish between monocyte/macrophage and
T cell sources, intracellular cytokine analysis was done exclusively
in the PerCP-labeled CD4 T cell population.
Data analysis
All values are expressed as mean6SD. The differences between
groups were analyzed by Mann-Whitney U test and, if
appropriate, by Kruskal-Wallis ANOVA test.
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